On-column disulfide bond formation of monoclonal antibodies during Protein A chromatography eliminates low molecular weight species and rescues reduced antibodies
Open Access
- 1 January 2020
- journal article
- other
- Published by Taylor & Francis in mAbs
- Vol. 12 (1) , 1829333
Abstract
Disulfide bond reduction, which commonly occurs during monoclonal antibody (mAb) manufacturing processes, can result in a drug substance with high levels of low molecular weight (LMW) species that may fail release specifications because the drug’s safety and the efficiency may be affected by the presence of this material. We previously studied disulfide reoxidation of mAbs and demonstrated that disulfide bonds could be reformed from the reduced antibody via redox reactions under an optimal redox condition on Protein A resin. The study here implements a redox system in a manufacturing setting to rescue the reduced mAb product and to further eliminate LMW issues in downstream processing. As such, we incorporate the optimized redox system as one of the wash buffers in Protein A chromatography to enable an on-column disulfide reoxidation to form intact antibody in vitro. Studies at laboratory scale (1 cm (ID) x 20 cm (Height), MabSelect SuRe LX) and pilot scale (30 cm (ID) x 20 cm (Height), MabSelect SuRe LX) were performed to demonstrate the effectiveness and robustness of disulfide formation with multiple mAbs using redox wash on Protein A columns. By applying this rescue strategy using ≤50 g/L-resin loading, the intact mAb purity was improved from 90% in the Protein A column elution with a product yield of >90%. Studies were also done to confirm that adding the redox wash has no negative impact on process yield or impurity removal or product quality. The rescued mAbs were confirmed to form complete interchain disulfide bonds, exhibiting comparable biophysical properties to the reference material. Furthermore, since the redox wash is followed by a bridging buffer wash before the final elution, no additional burden is involved in removing the redox components during the downstream steps. Due to its ease of implementation, significant product purity improvement, and minimal impact on other product quality attributes, we demonstrate that the on-column reoxidation using a redox system is a powerful, simple, and safe tool to recover reduced mAb during manufacturing. Moreover, the apparent benefits of using a high-pH redox wash may further drive the evolution of Protein A platform processes.Keywords
This publication has 51 references indexed in Scilit:
- A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacyBreast Cancer Research, 2012
- Disulfide bond structures of IgG moleculesmAbs, 2012
- Select host cell proteins coelute with monoclonal antibodies in protein a chromatographyBiotechnology Progress, 2011
- Identification and prevention of antibody disulfide bond reduction during cell culture manufacturingBiotechnology and Bioengineering, 2010
- Desulfurization of cysteine‐containing peptides resulting from sample preparation for protein characterization by mass spectrometryRapid Communications in Mass Spectrometry, 2010
- Design of therapeutic proteins with enhanced stabilityProceedings of the National Academy of Sciences, 2009
- Understanding the mechanism of virus removal by Q sepharose fast flow chromatography during the purification of CHO‐cell derived biotherapeuticsBiotechnology and Bioengineering, 2009
- Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit OperationsBiotechnology Progress, 2007
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- Convergent Solutions to Binding at a Protein-Protein InterfaceScience, 2000